Sector News

Genmab transfers its ofatumumab collaboration from GSK to Novartis

November 3, 2014
Life sciences
Danish biotech company Genmab has entered into an agreement with UK pharma major GlaxoSmithKline and Swiss drug major Novartis to transfer the ofatumumab collaboration, currently with GSK, to Novartis.
 
This follows an announcement in April 2014 that Novartis would acquire GSK’s oncology products, and the transfer of ofatumumab will only become effective on the closing of the GSK/Novartis transaction, expected in the first half of next year.
 
Upon transfer, Novartis is to develop and commercialize ofatumumab in oncology indications and GSK would continue to develop and commercialize the drug for autoimmune indications. The terms of the deal state that Genmab is not required to pay existing funding liabilities, or to fund research and development costs beyond December 31, 2014.
 
Jan van de Winkel, chief executive of Genmab, said: “The collaborations with Novartis and GSK for this innovative therapeutic antibody will help ofatumumab reach its fullest potential, while improving cash flows.”
 
Additionally, on completion of the transfer of the collaboration, Genmab will be able to develop follow-on CD20 products.
 

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]